Efficacy of naftopidil for LUTS in BPH with OAB patients

Efficacy of naftopidil for LUTS in BPH with OAB patients - Dose dependency of a1-blocker in its efficacy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010655

Enrollment

100

Registered

2013-05-07

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Naftopidil 8 weeks 50 mg /day once a day&quot

Naftopidil 8 weeks 75 mg /day once a day&quot

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) IPSS total score &sup3;8 2) Prostate volume &sup3;20 mL 3) Maximum flow rate <15 mL/s 4) Residual urine volume <100 mL 5) OABSS total score &sup3;3 and OABSS urgency score &sup3;2"

Exclusion criteria

Exclusion criteria: 1) With suspected neurogenic bladder associated with cerebral vascular disease, spinal cord injury, diabetes, etc. 2) With suspected prostate cancer 3) With urinary tract infection and urethral stricture 4) Taking radiotherapy in their pelvice 5) With serious disorder for heart, kidney, liver or blood 6) With taking a1-blocker within a last month"

Design outcomes

Primary

Measure	Time frame
IPSS OABSS OAB-q Uroflowmetry	—

Countries

Japan

Contacts

Public ContactSHIRAKAWA, Toshiro

Kobe University Graduate School of Medicine Urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026